Ivermectin + Fenbendazole + Targeted Therapy and Achieved 93% Tumor Volume Reduction in Stage IV Lung Cancer (Anonymized 2025–2026 Case Series)

By Editorial Team
Published by: Dr William Makis on X.com (May 4, 2026)
Edited and Reviewed by: OneDayMD Editorial Team

Important Medical Disclaimer

This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Repurposed drugs like ivermectin and fenbendazole are not approved by the FDA or any major regulatory body for cancer. Self-medication can cause serious side effects including liver toxicity, drug interactions, or delayed standard care. Always consult a qualified oncologist before considering any off-label protocol. Individual results vary widely and often reflect combined therapies. The case below is anonymized from a publicly shared patient report; outcomes are not guaranteed.


The Case Background

“Patient C.” is a 54-year-old woman diagnosed in July 2025 with Stage IV lung cancer (publicly described as NSCLC) with soft tissue metastases. The primary tumor measured 6.4 × 5.3 cm with SUVmax 9.5 on PET-CT. She also had intrathoracic lymph node metastases (up to 3.4 cm) and multiple soft tissue lesions. After starting conventional targeted therapy, she added repurposed agents under medical supervision.

The Protocol Used (August 2025 onward)

- Ivermectin + Fenbendazole: Added as repurposed agents (exact dosing not publicly detailed; managed privately).  

- Tagrisso (osimertinib): Standard targeted EGFR inhibitor continued as the backbone therapy.  

- Supportive measures (noted in follow-up reports): Brief pauses for monitoring, high-dose vitamin C IVs, and other supplements.  

- Monitoring: Serial whole-body PET-CT scans, bloodwork, and oncologist oversight. She had also received radiation to bone sites earlier in her course.  

The patient continued this integrated approach for 8 months.

Timeline & Outcomes (Anonymized Reports from Shared PET-CT)

- Baseline (July 2025): Primary right upper lobe mass 6.4 × 5.3 cm, SUVmax 9.5; multiple intrathoracic lymph nodes and soft tissue metastases.  

- December 2025 (≈4 months): Primary mass reduced to 3.5 × 2.3 cm, SUVmax 2.5; nodal and soft tissue lesions showed marked improvement.  

- March 2025 (≈8 months): Primary mass further reduced to 2.9 × 2.1 cm, SUVmax 2.4 (now at background level); all intrathoracic lymph node metastases resolved (100%); soft tissue metastases resolved (100%). No new lesions. The residual mass was described as centrally necrotic and metabolically inactive.  

Publicly shared imaging reports confirm “excellent near-complete metabolic treatment response” with continued interval improvement between scans.

Note: This was not repurposed drugs alone. The dramatic response occurred in the setting of ongoing Tagrisso therapy plus supportive care — a pattern frequently seen in patient-reported outcomes involving metabolic and repurposed approaches.

Why This Protocol May Have Contributed – The Science (Our Hallmarks Lens)

Ivermectin and fenbendazole have demonstrated multiple anti-cancer mechanisms in preclinical lung cancer models:

- Ivermectin: Inhibits mitochondrial function, disrupts PAK1 signaling, and promotes apoptosis in cells with high proliferative signaling. It may also enhance the effects of EGFR-targeted therapies like osimertinib.  

- Fenbendazole: Acts as a microtubule disruptor (similar to some chemotherapies) and mitochondrial uncoupler, targeting the “deregulating cellular energetics” and “resisting cell death” hallmarks.  

- Synergy with Tagrisso: Osimertinib blocks mutant EGFR-driven growth; the repurposed agents add metabolic stress, potentially overcoming resistance pathways common in advanced lung cancer.  

These mechanisms align with the updated 2026 Hallmarks of Cancer (sustaining proliferative signaling, deregulating cellular energetics, resisting cell death). While large randomized trials are still lacking, the metabolic targeting + repurposed drug combination continues to appear in observational reports like this one.

Lessons for Readers

This case highlights a recurring theme in integrative oncology: when standard targeted therapies begin to plateau or when patients seek additional options, carefully monitored repurposed metabolic agents may contribute to meaningful radiographic and clinical responses — even in metastatic disease. However, rigorous monitoring (liver function, drug levels, imaging) is essential, and results remain highly individual.

Important Medical Disclaimer (Repeated)

This is not medical advice. Ivermectin and fenbendazole are not approved for cancer treatment. Never discontinue or replace approved therapies without specialist guidance. Liver monitoring and oncologist supervision are mandatory. Consult your physician.


Related References:
  1. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients
  2. Ivermectin and Fenbendazole or Mebendazole in Cancer: Peer-Reviewed Protocol in Cancer
  3. Ivermectin and Cancer: Anti-cancer Mechanisms of Action
  4. Fenbendazole and Cancer: Anti-Cancer Mechanisms of Action
  5. AI Predicts Ivermectin and Mebendazole Combined with Pembrolizumab, Adagrasib, Nutraceuticals, and Tailored Diet/Lifestyle Improved Overall Survival in Stage 4 Non Small Cell Lung Cancer
  6. Drug Repurposing for Cancer Therapy 2025: From AI-Driven Discovery to Practice-Changing Clinical Trials.
  7. Fenbendazole and Other Stage 4 Cancer Types: The compilation includes over 300 stage 4 cancer case reports across 17 cancer types. Full details are provided in the following: Stage 4 Cancer Remissions with Fenbendazole, Ivermectin and Mebendazole (2026 Edition).
  8. Fenbendazole, Ivermectin and Mebendazole Cancer Success Stories: 700+ Case Reports Compilation of various stages (stages 1 to 4) of different cancer types (2026 Edition). (One Day MD 2026)
  9. Tagrisso (osimertinib) for EGFR mutated NSCLC (YouTube 2022)
  10. Lung Cancer Research and Clinical Management in 2026: Precision Oncology, Immunotherapy, and Emerging Signals From Drug Repurposing (Cancer Advisor 2026)

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more